In partnership with The ALS Association, NEALS offers a variety of educational webinars for the ALS community.
Outside of traditional clinical trials, expanded access is the only legal channel for physicians and their patients to explore unapproved medicine. This webinar explained the regulations and history of FDA-authorized expanded access and…
Dr. Richard Bedlack (Duke University) discussed ALSUntangled, which investigates alternative and off-label ALS treatments. He highlighted some recently completed reviews, new features, and how PALS can get involved. Watch it…
Dr. James Berry (Massachusetts General Hospital) provided an overview of the scientific rationale for this exciting \trial as well as discuss the next steps forward. **The TDI-132/Gilenya trial is not funded by The ALS Association.…
Robert Brown, DPhil, MD, (University of Massachusetts) highlighted ongoing genetic research in ALS and discussed implications for people living with ALS.
Nazem Atassi, MD, (Massachusetts General Hospital) discussed study rationale, preliminary results, and next steps for the selection trial.
Merit Cudkowicz, MD, (Massachusetts General Hospital) provided an overview of ALS treatments and discussed the state of ALS clinical research in 2013.
Jeremy Shefner, MD (SUNY Upstate Medical University), Jinsy Andrews, MD (Cytokinetics, Inc.), and Andrew Wolff, MD (Cytokinetics, Inc.) discussed rationale and background of the phase IIB trial of tirasmetiv in ALS.
Michael Weiss, MD (University of Washington) provided study rationale and background for the clinical trial of Mexiletine in patients with sporadic ALS (non-familial).
Merit Cudkowicz, MD, MSc (Massachusetts General Hospital) reviewed ALS symptoms and diagnosis, provided an overview of ALS treatments, and discussed the ALS clinical research pipeline.
Nicholas Maragakis, MD (Johns Hopkins University) presented rationale for the Exercise Trial in ALS, which is recruiting patients with ALS in Baltimore, Boston, St. Louis, and Charlotte, NC and includes an at-home exercise…